Aclaris Therapeutics Inc — Quarterly Cash Flow (NASDAQ:ACRS) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 220.33 M198.09 M189.15 M175.53 M160.46 M Total liabilities 64.77 M54.03 M57.41 M55.43 M57.38 M Total equity 155.55 M144.07 M131.74 M120.1 M103.08 M Total liabilities & shareholders' equities 220.33 M198.09 M189.15 M175.53 M160.46 M Total debt ————— Net debt —————

News

Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?

Aclaris Therapeutics stock rating reiterated at Buy by H.C. Wainwright

Stifel raises Aclaris Therapeutics stock price target to $3 on pipeline

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates

Aclaris Therapeutics Inc earnings missed by $0.01, revenue fell short of estimates

Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates

Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates

Aclaris starts phase 1b trial of ATI-052 in asthma patients

Craig-Hallum initiates coverage on Aclaris Therapeutics stock with Buy rating

Aclaris stock gets Buy rating reaffirmed by H.C. Wainwright after positive preclinical results

Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug - Aclaris Therapeutics (NASDAQ:ACRS)

Aclaris reports positive preclinical results for hair loss drug